Sagimet Biosciences to Participate in Two Upcoming Investor Conferences
- A fireside chat at the
TD Cowen 44th AnnualHealth Care Conference inBoston at2:10 p.m. ET /11:10 a.m. PT onMarch 5, 2024 ; and - A podium presentation at the
Leerink Partners Global Biopharma Conference 2024 inMiami at8:00 a.m. ET /5:00 a.m. PT onMarch 13, 2024 .
Webcasts of each presentation will be available in the Investors & Media section of Sagimet’s website at www.sagimet.com, with archived replays available for 90 days following the live event.
About Sagimet Biosciences
Sagimet is a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors that are designed to target dysfunctional metabolic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Sagimet’s lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of NASH, for which there are no treatments currently approved in
Contact:
ICR Westwicke
203-682-7167
maria.yonkoski@westwicke.com
Source: Sagimet Biosciences Inc.